Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Autor:	Paul Loubet, Benjamin Gaborit, Mathilde Salpin, Hèlene Gardeney, Ilies Benotmane, Thomas Systchenko
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	COVID-19 prophylaxis immunocompromised Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950
Zdroj:	Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	21645515 2164-554X 2164-5515
DOI:	10.1080/21645515.2024.2387221
Popis:	France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/1e33f7c4698e4801b92f13b3d35ed9e6 Zobrazit plný text záznamu View record in DOAJ